US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

26.44

-0.3650-1.36%

Volume:7K

Turnover:195.87K

Market Cap:59.35M

PE:- -

High:26.44

Open:26.43

Low:26.29

Close:26.80

52wk High:26.80

52wk Low:15.63

Shares:2.24M

Float Shares:2.24M

Volume Ratio:0.88

T/O Rate:0.33%

Dividend:1.70

Dividend Rate:6.45%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

GH Research Plc Q2 EPS USD -0.23

THOMSON REUTERS

GH Research Says H1 Loss Widens as R&D Spending Rises on GH001 Clinical, Technical Development Work

Scholar Rock Q2 Net Loss Narrows

GH Research Publishes Corporate Presentation on Ultra-Rapid, Durable Remission Data for TRD Treatment GH001

GH Research Q2 FY26 Net Loss Widens to $15.1 Million

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

THOMSON REUTERS

Challenger Gold Completes A$85m Raise and Reshapes Leadership for Next Growth Phase

Compass Pathways Grants New-Hire Inducement Equity Awards at USD 11.25 Per Share

Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Compass Pathways Plc Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing

THOMSON REUTERS

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA)

Compass Pathways PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Compass Pathways Publishes Investor Presentation on Comp360 Psilocybin Program, FDA Filing Progress and Launch Plans

Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs

Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate

Benzinga Earnings

Compass Pathways Q2 EPS USD -1.88

THOMSON REUTERS

Compass Pathways Q2 Operating Expenses USD 52.372 Million

THOMSON REUTERS

Press Release: Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Heavy Rare Earths plans major equity raising via pro rata offer and placement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PSIL/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":26.435,"timestamp":1787754661565,"preClose":26.8,"halted":0,"volume":7427,"delay":0,"changeRate":-0.013619402985074702,"floatShares":2244976,"shares":2244976,"eps":0,"marketStatus":"Trading","change":-0.365,"latestTime":"08-26 10:31:03 EDT","open":26.429,"high":26.435,"low":26.29,"amount":195870.310272,"amplitude":0.00541,"askPrice":26.63,"askSize":1000,"bidPrice":26.09,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":26.8,"sharesOutstanding":1184976,"nav":25.732,"aum":57766911.89,"dividendRate":0.064494,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":26.9,"preClose":26.8,"latestTime":"08:45 EDT","volume":844,"amount":22607.829632,"timestamp":1787748339359,"change":0.1,"changeRate":0.003731,"amplitude":0.033955},"postHourTrading":{"tag":"盘后","latestPrice":26.88,"preClose":26.8,"latestTime":"19:32 EDT","volume":216,"amount":5804.83,"timestamp":1787700759051,"change":0.08,"changeRate":0.002985,"amplitude":0.002985},"volumeRatio":0.884664,"impliedVol":0.4271,"impliedVolPercentile":0.7928},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2244976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.884664,"shares":2244976,"dividePrice":1.7049,"high":26.435,"amplitude":0.00541,"preClose":26.8,"low":26.29,"week52Low":15.6348,"pbRate":"--","week52High":26.8,"institutionHeld":0,"latestPrice":26.435,"committee":-0.818182,"eps":0,"divideRate":0.064494,"volume":7427,"delay":0,"ttmEps":0,"open":26.429,"prevYearClose":17.17,"prevWeekClose":25.86,"prevMonthClose":23.5,"prevQuarterClose":24.05,"fiveDayClose":26.24,"twentyDayClose":23.23,"sixtyDayClose":21.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657359246","title":"GH Research Plc Q2 EPS USD -0.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2657359246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657359246?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:42","pubTimestamp":1786016572,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXPBJD44:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GHRS","PSIL","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657926633","title":"GH Research Says H1 Loss Widens as R&D Spending Rises on GH001 Clinical, Technical Development Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2657926633","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657926633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:26","pubTimestamp":1786015613,"startTime":"0","endTime":"0","summary":"GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development workGH Research posted a net loss of USD 34.11 million for the six months ended June 30, 2026, driven by ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3lWYPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GHRS","BK4539","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657692633","title":"Scholar Rock Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657692633","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657692633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015339,"startTime":"0","endTime":"0","summary":"Scholar Rock Q2 net loss narrowsOverviewUS biopharmaceutical firm's Q2 net loss narrowed slightly yr/yr with no revenue recordedOperating expenses for Q2 fell, driven by reduced research and developme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BDTX","IBRN","BK4584","CMPS","MNKD","SRRK","BK4139","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633319","title":"GH Research Publishes Corporate Presentation on Ultra-Rapid, Durable Remission Data for TRD Treatment GH001","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633319","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633319?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:19","pubTimestamp":1786015157,"startTime":"0","endTime":"0","summary":"GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001GH Research highlighted Phase 2b data for GH001, an inhaled mebufotenin candidate for treatme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1w2P6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GHRS","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638668","title":"GH Research Q2 FY26 Net Loss Widens to $15.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638668?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:03","pubTimestamp":1786014184,"startTime":"0","endTime":"0","summary":"GH Research Q2 FY26 net loss widens to $15.1 millionGH Research posted a Q2 net loss of USD 15.1 million, or USD 0.23 per share, versus a USD 9.3 million loss a year earlier.R&D expenses climbed to US","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9LhCXq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","PSIL","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687402","title":"Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687402?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:42","pubTimestamp":1786012964,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44318H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657033945","title":"Challenger Gold Completes A$85m Raise and Reshapes Leadership for Next Growth Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2657033945","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657033945?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:59","pubTimestamp":1785981562,"startTime":"0","endTime":"0","summary":"Challenger Exploration Limited ( ($AU:CEL) ) has provided an update. Challenger Gold Limited has completed an A$85 million capital raising, includi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/challenger-gold-completes-a85m-raise-and-reshapes-leadership-for-next-growth-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/challenger-gold-completes-a85m-raise-and-reshapes-leadership-for-next-growth-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["518880","SGCmain","NUGT","DUST","GLD","MGCmain","PSIL","SGUmain","GDX","GCmain","159934","IAU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571589","title":"Compass Pathways Grants New-Hire Inducement Equity Awards at USD 11.25 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571589?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:48","pubTimestamp":1785966539,"startTime":"0","endTime":"0","summary":"Compass Pathways grants new-hire inducement equity awards at USD 11.25 per shareCompass Pathways granted equity awards to 14 newly hired non-executive employees on Aug. 3, 2026 under its 2026 Induceme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLbD8XbV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657738605","title":"Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657738605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657738605?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:30","pubTimestamp":1785961801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUAMJ72R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578488","title":"Compass Pathways Plc Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578488?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:23","pubTimestamp":1785961439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4421TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657152527","title":"Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657152527","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657152527?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:01","pubTimestamp":1785960060,"startTime":"0","endTime":"0","summary":"Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339642/0/en/Black-Diamond-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDTX","PSIL","BBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657522320","title":"Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657522320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657522320?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:50","pubTimestamp":1785955808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA). COMPASS ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-geron-gern-and-azenta-azta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-geron-gern-and-azenta-azta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","PSIL","BK4585","HCSG","LU0029874061.USD","IE00B7SZL793.SGD","LU2065732104.USD","IE0031619046.USD","LU1169589451.USD","BK4121","LABU","LU1169590202.USD","BK4581","BK4147","XBI","LU0012050646.USD","IE00B19Z4B17.USD","GERN","BK4137","CMPS","AZTA","LU0106261612.USD","BK4588","BK4139","IE00B66KJ199.SGD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540547","title":"Compass Pathways PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540547","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540547?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:32","pubTimestamp":1785936746,"startTime":"0","endTime":"0","summary":"Compass Pathways PLC reports results for the quarter ended June 30 - Earnings SummaryCompass Pathways PLCCMPS.OQreported a quarterly adjusted loss of $1.88 per share for the quarter ended June 30, low","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44224E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544828","title":"Compass Pathways Publishes Investor Presentation on Comp360 Psilocybin Program, FDA Filing Progress and Launch Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544828","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544828?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:07","pubTimestamp":1785931637,"startTime":"0","endTime":"0","summary":"Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plansCompass Pathways outlined plans to file a rolling NDA for COMP360 psilocybin in trea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9WMrTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545831","title":"Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545831?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:45","pubTimestamp":1785926714,"startTime":"0","endTime":"0","summary":"Compass Pathways' Q2 loss widens on commercial readiness activity costsOverviewUK mental health biotech's Q2 operating income missed analyst estimatesNet loss widened yr/yr, mainly due to non-cash war","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU1989772923.USD","LU2279689827.SGD","SG9999013999.USD","AZN.UK","LU1880407215.USD","LU2539964713.USD","LU0321505868.SGD","LU2237443978.SGD","LU1481600234.SGD","SGXZ57979304.SGD","LU1057294990.SGD","LIVN","CMPS","LU0203345920.USD","LU0997586432.USD","LU0575583348.USD","LU1718418525.SGD","LU0526926950.USD","BK4007","LU2596442595.SGD","LU0096364046.USD","LU0757432116.USD","LU0211326839.USD","LU2065171311.SGD","LU0310799852.SGD","03165","LU2065170008.USD","BMY","PSIL","LU0985481810.HKD","LU0432979614.USD","LU2125154935.USD","ACAD","LU1046234339.USD","LU1863844749.USD","LU1291159041.SGD","LU1670710588.SGD","LU0266013472.USD","LU1273509221.SGD","LU0496365809.HKD","LU1983299246.USD","IHE","LU1153585028.USD","LU0306807586.USD","LU2089284900.SGD","LFSC","LU1196032939.SGD","FTXH","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657254330","title":"Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657254330","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657254330?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:33","pubTimestamp":1785925989,"startTime":"0","endTime":"0","summary":"Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.37) by 408.11 percent. This is a 358.54 percent decrease over losses of $(0.41) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60941435/compass-pathways-q2-eps-1-88-misses-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548774","title":"Compass Pathways Q2 EPS USD -1.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548774?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXD2DKG4:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548002","title":"Compass Pathways Q2 Operating Expenses USD 52.372 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548002?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXD2DKG4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657354829","title":"Press Release: Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657354829","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657354829?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":"--  Data from two positive Phase 3 trials demonstrated rapid onset of. effect and durable benefit through at least 6 months, further validating. COMP360's potential to establish a new standard of care in TRD. --  COMP360 has a highly differentiated clinical profile and is expected to. --  Rolling NDA submission and initial review underway and final submission. --  Commercial launch expected in first half of 2027. --  COMP360 expected to fit seamlessly into current treatment. --  Strong cash position of $433 million at the end of second quarter,--  Compass management will host a conference call on August 5 at 8:00 am. options in mental health care -- moving beyond daily or frequent. administration toward an option that could potentially provide strong. efficacy with just a few treatments a year that could be life changing. --  Across two highly statistically significant positive Phase 3 trials,COMP360 is the first classic psychedelic1 to consistently demonstrate. rapid onset, sustained ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4194","BK4139","CMPS","BK4223","NPV","DEA","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657951495","title":"Heavy Rare Earths plans major equity raising via pro rata offer and placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657951495","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657951495?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:37","pubTimestamp":1785890250,"startTime":"0","endTime":"0","summary":"Heavy Rare Earths Limited ( ($AU:HRE) ) has issued an announcement. Heavy Rare Earths Limited has lodged details of a proposed capital raising with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/heavy-rare-earths-plans-major-equity-raising-via-pro-rata-offer-and-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/heavy-rare-earths-plans-major-equity-raising-via-pro-rata-offer-and-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","SETM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}